There are still some limitations in our study: first, we will further collect and expand HCC cohorts to validate the reliability of the risk model; second, molecular mechanisms for NNMT‐mediated RAC3 activated pathways are not well established. The gene discussed is RAC3; the disease is hepatocellular carcinoma.